Use of anti-X a activity as a marker for heparin-induced bleeding in patients with APTT > 180 s
Haliassos, A.; Melita-Manolis, H.; Aggelaki, D.; Tassi, D.; Terzoglou, G.
Clinical Chemistry 43(9): 1781-1782
1997
ISSN/ISBN: 0009-9147 PMID: 9299975 Document Number: 471481
Document emailed within 1 workday
Related Documents
Tanaka, N.; Manabe, M.; Yamashita, S.; Ikeda, K.; Obayashi, K.; Uchiba, M.; Ando, Y. 2013: Comparison of heparin-induced prolongation of APTT in 12 different laboratories in Kyushu area Rinsho Byori. Japanese Journal of Clinical Pathology 61(7): 576-582Sampol, J.; Rossi, J.M.; Lejay, G. 1984: Automatization of heparin determination using chronometric evaluation of anti-Xa activity of the AT III-heparin complex Annales de Biologie Clinique 42(1): 21-23
Betjes, M.G.H.; van Oosterom, D.; van Agteren, M.; van de Wetering, J. 2007: Regional citrate versus heparin anticoagulation during venovenous hemofiltration in patients at low risk for bleeding: similar hemofilter survival but significantly less bleeding Journal of Nephrology 20(5): 602-608
Niermeiier, P.; Gips, C.H.; Huizenga, J.R.; Ringers, J.; Verkerk, S.; Houthuff, H.J.; Houwen, B.; Snijder, J.A.; Nielsen, J.O. 1978: IgM-anti-HBc as a marker of persistent and IgG-anti-HBc as a marker of past hepatitis B infection. a longitudinal study over 5 years Acta Hepato-Gastroenterologica 25(5): 360-364
Suehiro, S.; Shibata, T.; Sasaki, Y.; Hattori, K.; Kumano, H.; Hosono, M.; Kinoshita, H. 1999: Use of heparin-coated cardiopulmonary bypass circuit with low-dose heparin reduces postoperative bleeding Annals of Thoracic and Cardiovascular Surgery: Official Journal of the Association of Thoracic and Cardiovascular Surgeons of Asia 5(4): 225-229
White, M.M.; Siders, L.; Jennings, L.K.; White, F.L. 1992: The effect of residual heparin on the interpretation of heparin-induced platelet aggregation in the diagnosis of heparin-associated thrombocytopenia Thrombosis and Haemostasis 68(1): 88
Buccianti, G.; Valenti, G.; Lorenz, M.; Cresseri, D.; Strada, E.; Nazzari, M. 1990: Kinetics of anti-Xa activity during combined defibrotide-heparin administration in hemodialysis International Journal of Artificial Organs 13(7): 416-420
Lai, S.; Barbano, B.; Cianci, R.; Gigante, A.; Di Donato, D.; Asllanaj, B.; Dimko, M.; Mariotti, A.; Morabito, S.; Pugliese, F. 2010: The risk of bleeding associated with low molecular weight heparin in patients with renal failure Giornale Italiano di Nefrologia: Organo Ufficiale Della Societa Italiana di Nefrologia 27(6): 649-654
Toppozada, M.; Anwar, M.; Abdel Rahman, H.; Gaweesh, S. 1982: Control of IUD-induced bleeding by three non-steroidal anti-inflammatory drugs Contraceptive Delivery Systems 3(2): 117-125
Barrowcliffe, T.W.; Le Shirley, Y. 1989: The effect of calcium chloride on anti-Xa activity of heparin and its molecular weight fractions Thrombosis and Haemostasis 62(3): 950-954
Zivković, V.; Stanković, A.; Cvetković, T.; Mitić, B.; Kostić, S.; Nedović, J.; Stamenković, B. 2014: Anti-dsDNA, anti-nucleosome and anti-C1q antibodies as disease activity markers in patients with systemic lupus erythematosus Srpski Arhiv Za Celokupno Lekarstvo 142(7-8): 431-436
Brieger, D.; Dawes, J. 1994: Characterisation of persistent anti-Xa activity following administration of the low molecular weight heparin enoxaparin sodium (Clexane) Thrombosis and Haemostasis 72(2): 275-280
Petitou, M.; Lormeau, J.C.; Choay, J. 1991: A new synthetic pentasaccharide with increased anti-factor Xa activity: possible role for anionic clusters in the interaction of heparin and antithrombin IIi Seminars in Thrombosis and Hemostasis 17(Suppl 2): 143-146
Lebacq, A.M.; Goffinet, P.; De Bruyere, M.; Rodhain, J.; Sokal, G. 1982: Membrane marker studies with anti-T, anti-Ia (DR) and anti-myeloblast antisera in acute leukaemias European Journal of Cancer and Clinical Oncology 18(2): 147-153
Zhang, L.; Zhang, G. 1999: Thrombosis induced by homocysteine does not depend on platelet aggregation or heparin cofactor's antithrombin activity Hunan Yi Ke da Xue Xue Bao 24(4): 309
Wager, O.; Räsänen, J.A.; Haltia, K.; Wasastjerna, C. 1971: M components with antibody activity. Anti-smooth muscle, anti-thyroglobulin and anti-streptolysin-O activity in five M component sera Annals of Clinical Research 3(2): 86-97
Huisse, M.G.; Huet, Y.; Zygelman, M.; Guillin, M.C. 1983: Thrombopenia induced by standard heparin. Therapeutic attempt using a low molecular weight heparin Presse Medicale 12(10): 643
Párama, J.A.; Llorens, R.; Sáenz de Buruaga, J.; Rocha, E. 1994: Low-molecular-weight heparin in a patient with heparin-induced thrombocytopenia and a cardiopulmonary bypass Medicina Clinica 102(16): 637-638
Izban, K.F.; Lietz, H.W.; Hoppensteadt, D.A.; Jeske, W.P.; Fareed, J.; Bakhos, M.; Walenga, J.M. 1999: Comparison of two PF4/heparin ELISA assays for the laboratory diagnosis of heparin-induced thrombocytopenia Seminars in Thrombosis and Hemostasis 25(Suppl 1): 51-56
Kanno, M.; Edanaga, M.; Mizukami, N.; Tokinaga, Y.; Niiyama, Y.; Yamakage, M. 2015: Successful Management of Cardiopulmonary Bypass Using Heparin in a Patient with Previous History of Heparin-induced Thrombocytopenia Masui. Japanese Journal of Anesthesiology 64(4): 449-452